Related Experiment Videos
Prognostic factors in superficial bladder cancer
D K Chopin1, Z Popov, V Ravery
1CRCHM, Service d'Urologie, Hôpital Henri Mondor, Creteil, France.
World Journal of Urology
|January 1, 1993
Summary
Intravesical bacillus Calmette-Guérin (BCG) therapy shows promise for superficial bladder cancer. Identifying prognostic factors is crucial for tailoring treatment and improving patient outcomes.
Area of Science:
- Urology
- Oncology
- Cancer Research
Background:
- Superficial bladder cancer management benefits from intravesical bacillus Calmette-Guérin (BCG) prophylaxis.
- Prognostic factors are essential for guiding treatment decisions between conservative and radical approaches.
- Improving oncological outcomes and patient quality of life remains a key objective.
Purpose of the Study:
- To review current knowledge on prognostic factors in superficial bladder cancer.
- To evaluate the utility and limitations of clinicopathological parameters, quantitative analysis, and biological markers.
- To highlight how prognostic factors can refine treatment strategies.
Main Methods:
- Literature review of studies on prognostic factors in superficial bladder cancer.
- Analysis of information from clinicopathological parameters, quantitative analysis, and biological markers.
- Evaluation of recent advances, limitations, and pitfalls in prognostication.
Main Results:
- Evidence supports bacillus Calmette-Guérin (BCG) intravesical prophylaxis for superficial bladder cancer.
- Prognostic factors are categorized into clinicopathological, quantitative, and biological markers.
- Understanding these factors is key to optimizing treatment selection.
Conclusions:
- Prognostic factors are vital for personalized treatment of superficial bladder cancer.
- Advances in identifying and utilizing these factors are improving patient care.
- Effective application of prognostic information will shape future management strategies.